MX355422B - Derivados de 1,3-dihidroimidazol-2-tiona para el uso en el tratamiento de hipertension arterial pulmonar y daño pulmonar. - Google Patents
Derivados de 1,3-dihidroimidazol-2-tiona para el uso en el tratamiento de hipertension arterial pulmonar y daño pulmonar.Info
- Publication number
- MX355422B MX355422B MX2015005910A MX2015005910A MX355422B MX 355422 B MX355422 B MX 355422B MX 2015005910 A MX2015005910 A MX 2015005910A MX 2015005910 A MX2015005910 A MX 2015005910A MX 355422 B MX355422 B MX 355422B
- Authority
- MX
- Mexico
- Prior art keywords
- arterial hypertension
- pulmonary arterial
- dihydroimidazole
- treatment
- lung injury
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/417—Imidazole-alkylamines, e.g. histamine, phentolamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/16—Central respiratory analeptics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/02—Nutrients, e.g. vitamins, minerals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/10—Antioedematous agents; Diuretics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/06—Antiarrhythmics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Epidemiology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Pulmonology (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Neurology (AREA)
- Vascular Medicine (AREA)
- Pain & Pain Management (AREA)
- Biomedical Technology (AREA)
- Urology & Nephrology (AREA)
- Neurosurgery (AREA)
- Nutrition Science (AREA)
- Obesity (AREA)
- Dermatology (AREA)
- Hospice & Palliative Care (AREA)
- Otolaryngology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
La presente invención se relaciona con compuestos de la fórmula I: para el uso en el tratamiento de hipertensión arterial pulmonar y las afecciones asociadas, en donde R1, R2 y R3 son el mismo o diferentes y significan hidrógenos, halógenos, alquilo, alquilarilo, alquiloxi, hidroxi, nitro, amino, alquilcarbonilamino, alquilamino o un grupo dialquilamino; R4 significa hidrógeno, alquilo, -alquilarilo o -alquilheteroarilo; X significa CH2, un átomo de oxígeno o átomo de azufre; n es 1, 2 ó 3, con la condición de que cuando n es 1, X no sea CH2 y los enantiómeros individuales (R)- y (S) o mezclas de enantiómeros y las sales farmacéuticamente aceptables de los mismos.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201261726119P | 2012-11-14 | 2012-11-14 | |
PCT/PT2013/000065 WO2014077715A1 (en) | 2012-11-14 | 2013-11-14 | 1,3-dihydroimidazole-2-thione derivatives for use in the treatment of pulmonary arterial hypertension and lung injury |
Publications (2)
Publication Number | Publication Date |
---|---|
MX2015005910A MX2015005910A (es) | 2015-08-10 |
MX355422B true MX355422B (es) | 2018-04-18 |
Family
ID=49759506
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2015005910A MX355422B (es) | 2012-11-14 | 2013-11-14 | Derivados de 1,3-dihidroimidazol-2-tiona para el uso en el tratamiento de hipertension arterial pulmonar y daño pulmonar. |
Country Status (23)
Country | Link |
---|---|
US (3) | US9604970B2 (es) |
EP (1) | EP2919780B1 (es) |
JP (1) | JP6373275B2 (es) |
KR (1) | KR102259938B1 (es) |
CN (1) | CN105025895B (es) |
AU (1) | AU2013345494B2 (es) |
BR (1) | BR112015010969B1 (es) |
CA (1) | CA2890920C (es) |
CY (1) | CY1120953T1 (es) |
DK (1) | DK2919780T3 (es) |
ES (1) | ES2693025T3 (es) |
HK (1) | HK1215393A1 (es) |
HR (1) | HRP20181651T1 (es) |
IN (1) | IN2015DN04089A (es) |
LT (1) | LT2919780T (es) |
MX (1) | MX355422B (es) |
PL (1) | PL2919780T3 (es) |
PT (1) | PT2919780T (es) |
RS (1) | RS57874B1 (es) |
RU (1) | RU2718055C2 (es) |
SI (1) | SI2919780T1 (es) |
TR (1) | TR201815850T4 (es) |
WO (1) | WO2014077715A1 (es) |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA2890920C (en) | 2012-11-14 | 2020-12-15 | Bial - Portela & Ca, S.A. | 1,3-dihydroimidazole-2-thione derivatives for use in the treatment of pulmonary arterial hypertension and lung injury |
GB201810395D0 (en) * | 2018-06-25 | 2018-08-08 | Bial Portela & Ca Sa | Formulations comprising dopamine-beta-hydroxylase inhibitors and methods for their preparation |
WO2021005623A1 (en) * | 2019-07-08 | 2021-01-14 | Msd Wellcome Trust Hilleman Laboratories Pvt. Ltd. | A vaccine formulation for protection against enterotoxigenic e. coli (etec) and cholera |
Family Cites Families (17)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH0623107B2 (ja) * | 1990-11-16 | 1994-03-30 | 帝人株式会社 | プロスタサイクリン類を有効成分とする薬学的組成物 |
WO1995029165A2 (en) * | 1994-04-26 | 1995-11-02 | Syntex (U.S.A.) Inc. | Benzocycloalkylaz0lethione derivatives as dopamin beta-hydroxylase inhibitors |
TW536540B (en) | 1997-01-30 | 2003-06-11 | Bristol Myers Squibb Co | Endothelin antagonists: N-[[2'-[[(4,5-dimethyl-3-isoxazolyl)amino]sulfonyl]-4-(2-oxazolyl)[1,1'-biphenyl]-2-yl]methyl]-N,3,3-trimethylbutanamide and N-(4,5-dimethyl-3-isoxazolyl)-2'-[(3,3-dimethyl-2-oxo-1-pyrrolidinyl)methyl]-4'-(2-oxazolyl)[1,1'-biphe |
US7125904B2 (en) * | 2002-10-11 | 2006-10-24 | Portela & C.A., S.A. | Peripherally-selective inhibitors of dopamine-β-hydroxylase and method of their preparation |
US20040102361A1 (en) * | 2002-11-27 | 2004-05-27 | Frederic Bodin | Pharmaceutical composition for the treatment of pulmonary arterial hypertension |
GB0600709D0 (en) | 2006-01-13 | 2006-02-22 | Portela & Ca Sa | Drug combinations |
GB0610804D0 (en) * | 2006-05-31 | 2006-07-12 | Portela & Ca Sa | New crystal forms |
GB0700635D0 (en) | 2007-01-12 | 2007-02-21 | Portela & Ca Sa | Therapy |
EP2146707A2 (en) * | 2007-05-03 | 2010-01-27 | Abraxis BioScience, LLC | Methods and compositions for treating pulmonary hypertension |
GB0708818D0 (en) * | 2007-05-08 | 2007-06-13 | Portela & Ca Sa | Compounds |
EP2231648A1 (en) * | 2007-12-05 | 2010-09-29 | BIAL - Portela & Ca., S.A. | New salts and crystal forms |
EP2224927B1 (en) | 2008-01-03 | 2014-08-20 | BioMarin Pharmaceutical Inc. | Pterin analog for treating bh4 responsive condition |
AR070841A1 (es) * | 2008-03-13 | 2010-05-05 | Bial Portela & Ca Sa | Proceso de hidrogenacion catalitica asimetrica |
AR071632A1 (es) * | 2008-05-06 | 2010-06-30 | Bial Portela & Ca Sa | Proceso catalitico para hidrogenacion asimetrica en la sintesis de inhibidores de la dopamina-beta-hidroxilasa" |
DE102008054205A1 (de) * | 2008-10-31 | 2010-05-06 | Bayer Schering Pharma Aktiengesellschaft | Verwendung von Helium-Sauerstoff-Gasgemischen zur Behandlung der pulmonalen arteriellen Hypertonie |
PT2655363T (pt) * | 2010-12-22 | 2017-07-13 | Bial-Portela & Ca S A | Formas cristalinas e processos para a sua preparação |
CA2890920C (en) | 2012-11-14 | 2020-12-15 | Bial - Portela & Ca, S.A. | 1,3-dihydroimidazole-2-thione derivatives for use in the treatment of pulmonary arterial hypertension and lung injury |
-
2013
- 2013-11-14 CA CA2890920A patent/CA2890920C/en active Active
- 2013-11-14 WO PCT/PT2013/000065 patent/WO2014077715A1/en active Application Filing
- 2013-11-14 IN IN4089DEN2015 patent/IN2015DN04089A/en unknown
- 2013-11-14 BR BR112015010969-1A patent/BR112015010969B1/pt not_active IP Right Cessation
- 2013-11-14 LT LTEP13803292.5T patent/LT2919780T/lt unknown
- 2013-11-14 PT PT13803292T patent/PT2919780T/pt unknown
- 2013-11-14 CN CN201380059547.2A patent/CN105025895B/zh not_active Expired - Fee Related
- 2013-11-14 EP EP13803292.5A patent/EP2919780B1/en active Active
- 2013-11-14 MX MX2015005910A patent/MX355422B/es active IP Right Grant
- 2013-11-14 TR TR2018/15850T patent/TR201815850T4/tr unknown
- 2013-11-14 ES ES13803292.5T patent/ES2693025T3/es active Active
- 2013-11-14 RS RS20181204A patent/RS57874B1/sr unknown
- 2013-11-14 RU RU2015120164A patent/RU2718055C2/ru not_active Application Discontinuation
- 2013-11-14 AU AU2013345494A patent/AU2013345494B2/en not_active Ceased
- 2013-11-14 JP JP2015542997A patent/JP6373275B2/ja not_active Expired - Fee Related
- 2013-11-14 KR KR1020157014363A patent/KR102259938B1/ko active IP Right Grant
- 2013-11-14 DK DK13803292.5T patent/DK2919780T3/en active
- 2013-11-14 PL PL13803292T patent/PL2919780T3/pl unknown
- 2013-11-14 SI SI201331204T patent/SI2919780T1/sl unknown
- 2013-11-14 US US14/441,043 patent/US9604970B2/en active Active
-
2016
- 2016-03-23 HK HK16103398.4A patent/HK1215393A1/zh not_active IP Right Cessation
-
2017
- 2017-02-14 US US15/432,616 patent/US10308640B2/en not_active Expired - Fee Related
-
2018
- 2018-10-11 HR HRP20181651TT patent/HRP20181651T1/hr unknown
- 2018-10-30 CY CY20181101117T patent/CY1120953T1/el unknown
-
2019
- 2019-04-16 US US16/385,350 patent/US20190241545A1/en not_active Abandoned
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
GEP201606532B (en) | Benzamide derivatives for inhibiting the activity of abl1, abl2 and bcr-abl1 | |
NZ733899A (en) | [9,10-dimethoxy-3-(2-methylpropyl)-1h,2h,3h,4h,6h,7h,11bh-pyrido-[2,1-a]isoquinolin-2-yl]methanol and compounds, compositions and methods relating thereto | |
TW200612958A (en) | Substituted imidazole derivatives | |
GB0708818D0 (en) | Compounds | |
CR20200286A (es) | DERIVADOS DE DIHIDRO-BENZO-OXAZINA Y DIHIDRO-PIRIDO-OXAZINA (Divisional 2014-0294) | |
CY1117792T1 (el) | Ανταγωνιστες toy trpv4 | |
MD4425B1 (ro) | Alcoxipirazoli în calitate de activatori ai guanilatciclazei solubile | |
UA108510C2 (en) | Cyclopropane compound | |
TN2009000287A1 (en) | Cyclized derivatives as eg-5inhibitors | |
PH12018502457A1 (en) | Treatment for parkinson's disease | |
MX2012007896A (es) | Derivados de piridino-piridinonas arilsulfonamidas, su preparacion y su uso en terapeutica. | |
NZ702357A (en) | 5,6-benzoflavone compositions for treating and/or preventing skin disease associated with hyperseborrhea | |
MX2020005735A (es) | Derivados de glutarimida, uso de los mismos, composición farmacéutica basada en los mismos y métodos para producir derivados de glutarimida. | |
MY178106A (en) | 1,4-butanediol-containing composition | |
NZ734260A (en) | Substituted triazoles and methods relating thereto | |
CY1120953T1 (el) | Παραγωγα 1,3-διυδροϊμιδαζολο-2-θειονης για χρηση στην αγωγη πνευμονικης αρτηριακης υπερτασης και πνευμονικης βλαβης | |
PH12015502429A1 (en) | Dicarboxylic acid compound | |
WO2012122028A3 (en) | Pyrazinoisoquinoline compounds | |
PH12015500012B1 (en) | Benzodioxole derivative and preparation method and use thereof | |
MX2015007424A (es) | Composiciones y/o articulos con solubilidad mejorada de un activo solido. | |
MX2015010087A (es) | Derivados de catecolamina enriquecidos con deuterio asimetrico posicion-especifico y medicamentos que comprenden los compuestos. | |
EA201491878A1 (ru) | Замещенные ксантиновые производные | |
MX2016003211A (es) | Procesos para la preparacion de medicamentos para el tratamiento de enfermedades cardiovasculares y compuestos intermedios para uso en los mismos. | |
MX362478B (es) | Derivado de benzoazepina novedoso y uso medico del mismo. | |
MX2009007329A (es) | 1,3-dihidroimidazoles para tratar trastornos cardiovasculares. |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FG | Grant or registration |